Balanced news tone
News Sentiment
CYC sentiment intelligence
Cyclopharm Limited news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Weighted score
51
Balanced news tone
19 relevant articles
Price is moving more forcefully than the current news tone suggests.
91/100 classification confidence.
directly relevant articles
high-authority source matches
+6.1% over one week, -8.7% over four weeks, trend inactive, and below fair value.
Cyclopharm Ltd (ASX:CYC) Jumps 25.77% as Shares Reach AUD 0.61
Market Reaction
Price moving ahead of tone
Price is moving more forcefully than the current news tone suggests.
Primary event
Market update
91/100 classification
One-week reaction
6.1%
Price confirming higher
Trend fit
Trend inactive
-8.7% over four weeks
Fair value
-63.1%
Below fair value
Value support
Sentiment Mix
Positive, neutral, negative
Positive
3
Neutral
14
Negative
2
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
Above 50
Neutral zone
Below 50
News Tape
Relevant headlines
Kalkine
Direct company coverage
Cyclopharm Ltd (ASX:CYC) Jumps 25.77% as Shares Reach AUD 0.61
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 15 Jul 2026 10:09
- Source
- Kalkine
grafa.com
Direct company coverage
Australia's Cyclopharm secures 11-site agreement in US
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 15 Jul 2026 06:02
- Source
- grafa.com
Stocks Down Under
Direct company coverage
Cyclopharm (ASX:CYC) locks in 11-site University Hospitals rollout with no staged delay
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 15 Jul 2026 00:21
- Source
- Stocks Down Under
TipRanks
Direct company coverage
Cyclopharm Adjusts Capital Structure as Conditional Share Rights Lapse
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 06 Jul 2026 05:20
- Source
- TipRanks
Kalkine
Direct company coverage
Cyclopharm (ASX:CYC): Healthcare Stock in Focus Amid Commercialisation Progress
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 01 Jul 2026 07:00
- Source
- Kalkine
Kalkine
Direct company coverage
Cyclopharm Slides as Healthcare Growth Stocks Face Pressure
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 30 Jun 2026 06:42
- Source
- Kalkine
Kalkine
Direct company coverage
Will Cyclopharm’s (ASX:CYC) UPHS Agreement Accelerate US Expansion?
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 23 Mar 2026 07:00
- Source
- Kalkine
BiotechDispatch
Direct company coverage
Cyclopharm completes sale of cyclotron asset to strengthen focus on Technegas expansion
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 12 Nov 2025 08:00
- Source
- BiotechDispatch
smallcaps.com.au
Direct company coverage
Insights: Cyclopharm Ltd (ASX:CYC)
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 30 Oct 2025 14:12
- Source
- smallcaps.com.au
Stocks Down Under
Direct company coverage
Cyclopharm (ASX:CYC): FDA approved for 2 years now, but a lawsuit from 4DX is the latest headache and cause for investor scepticism
- Tone
- Negative 34/100
- Event
- Regulatory and legal
- Published
- 08 Oct 2025 07:00
- Source
- Stocks Down Under
The Nightly
Direct company coverage
Rival biotechs 4D Medical, Cyclopharm in $24m court battle
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 06 Oct 2025 07:00
- Source
- The Nightly
simplywall.st
Direct company coverage
Cyclopharm (ASX:CYC investor three-year losses grow to 43% as the stock sheds AU$19m this past week
- Tone
- Negative 34/100
- Event
- Market update
- Published
- 04 Sep 2025 07:00
- Source
- simplywall.st
simplywall.st
Direct company coverage
Cyclopharm Limited (ASX:CYC) Could Be Less Than A Year Away From Profitability
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 04 Jul 2025 07:00
- Source
- simplywall.st
Stockhead
Direct company coverage
Biocurious: Lung imager Cyclopharm is breathing easy in the US market
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 29 Jan 2025 08:00
- Source
- Stockhead
Stocks Down Under
Direct company coverage
Investors in Cyclopharm shares (ASX:CYC) just received some welcome clarity on the FDA approval process
- Tone
- Neutral 50/100
- Event
- Regulatory and legal
- Published
- 09 May 2023 07:00
- Source
- Stocks Down Under
intelligentinvestor.com.au
Direct company coverage
Cyclopharm Limited (ASX: CYC) - Dividends
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 01 Oct 2019 04:30
- Source
- intelligentinvestor.com.au
intelligentinvestor.com.au
Direct company coverage
Cyclopharm Limited (ASX:CYC) - Shares, Dividends & News
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 23 Sep 2019 12:27
- Source
- intelligentinvestor.com.au
TradingView
Direct company coverage
CYC Stock Price and Chart — ASX:CYC
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 06 Oct 2017 02:17
- Source
- TradingView
The Motley Fool Australia
Direct company coverage
Cyclopharm Ltd (ASX: CYC)
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 01 Oct 2015 19:28
- Source
- The Motley Fool Australia